September 30, 2019 Life Science Tools PR/Corporate

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa

Basel, 30 September 2019 Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa Efficacy of Alecensa® (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal... Read more

September 28, 2019 PR/Corporate Product Launch

Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer

Basel, 28 September 2019 Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer New real-world data from the Flatiron database supports clinical benefits of Alecensa® (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival... Read more

September 27, 2019 Atomic Spectroscopy Bio/Pharma/CRO PR/Corporate

Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma

Basel, 27 September 2019 Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination... Read more

September 27, 2019 PR/Corporate

We have issued "Annual Report 2019".

This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more

September 26, 2019 PR/Corporate

Eppendorf significantly expands production site in Oldenburg

Construction of two new production halls to manufacture high-quality laboratory consumables for the global life science market Substantial capacity increase by 30 percent from 2021 Creation of up to 60 new skilled jobs Hamburg and Oldenburg in Holstein, Germany, September 25, 2019 The Eppendorf Group is boosting its production capacity at its site in Oldenburg... Read more

September 25, 2019 Lab Top-10 PR/Corporate

Thermo Fisher Scientific Prices Offering of Senior Notes

WALTHAM, Mass., Sept. 25, 2019 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher“) announced today that it has priced an offering of €4.4 billion aggregate principal amount (the “Euro Offering”) of euro-denominated notes (collectively, the “Euro Notes”) and an offering of $900 million aggregate principal amount (the “USD Offering” and, together with the Euro... Read more

September 23, 2019 PR/Corporate

Tony Hyman receives Carl Zeiss Lecture 2019

Understanding the mechanisms of cell division News This year’s awardee of the Carl Zeiss Lecture, the most visible prize of the German Society for Cell Biology (DGZ), is Anthony A. Hyman, director at the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) in Dresden. At the MPI-CBG 500 curiosity-driven scientists from over 50... Read more

September 23, 2019 Clinical Research/Diagn. PR/Corporate

Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress

Basel, 23 September 2019 Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medicine’s FoundationOne® Liquid biopsy assay... Read more

September 23, 2019 PAI Top-10 PR/Corporate

Tony Hyman Receives Carl Zeiss Lecture 2019

Understanding the mechanisms of cell division This year’s awardee of the Carl Zeiss Lecture, the most visible prize of the German Society for Cell Biology (DGZ), is Anthony A. Hyman, director at the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) in Dresden. At the MPI-CBG 500 curiosity-driven scientists from over 50 countries do pioneering basic... Read more

September 20, 2019 Lab Top-10 PR/Corporate

Envista Announces IPO Closing

BREA, Calif., Sept. 20, 2019 /PRNewswire/ — Envista Holdings Corporation, a subsidiary of Danaher Corporation (NYSE: DHR), today announced the closing of its previously announced initial public offering (IPO) of 26,768,000 shares of its common stock at a price to the public of $22.00 per share. In connection with the IPO, the underwriters exercised in... Read more